HTG MOLECULAR DIAGNOSTICS, INC 4
4 · HTG MOLECULAR DIAGNOSTICS, INC · Filed May 13, 2015
Insider Transaction Report
Form 4
George Harry A.
Director
Transactions
- Conversion
Common Stock
2015-05-11+17,321→ 122,008 total(indirect: By Entities affiliated with Solstice Capital) - Conversion
Common Stock
2015-05-11+1,178→ 144,366 total(indirect: By Entities affiliated with Solstice Capital) - Conversion
Series B Convertible Preferred Stock
2015-05-11−1,895,946→ 0 total(indirect: By Entities affiliated with Solstice Capital)→ Common Stock (21,180 underlying) - Exercise of In-Money
Series D Convertible Preferred Stock
2015-05-11+126,535→ 126,535 total(indirect: By Entities affiliated with Solstice Capital)→ Common Stock (1,178 underlying) - Conversion
Common Stock
2015-05-11+21,180→ 143,188 total(indirect: By Entities affiliated with Solstice Capital) - Conversion
Series A Convertible Preferred Stock
2015-05-11−574,212→ 0 total(indirect: By Entities affiliated with Solstice Capital)→ Common Stock (17,321 underlying) - Exercise of In-Money
Series D Convertible Preferred Stock Warrant (right to buy)
2015-05-11−126,535→ 0 total(indirect: By Entities affiliated with Solstice Capital)From: 2010-07-30Exp: 2020-07-29→ Series D Convertible Preferred Stock (126,535 underlying) - Conversion
Series D Convertible Preferred Stock
2015-05-11−126,535→ 0 total(indirect: By Entities affiliated with Solstice Capital)→ Common Stock (1,178 underlying)
Footnotes (4)
- [F1]Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1 for 107.39 basis, after accounting for any applicable antidilution adjustments. The shares have no expiration date.
- [F2]The Reporting Person is the managing member of Solstice Capital and has joint voting and investment power over the shares held by Solstice Capital.
- [F3]The warrant was net exercised for shares of common stock upon the closing of the Issuer's initial public offering.
- [F4]The shares of Series D Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder without payment of further consideration. Each share of Series D Convertible Preferred Stock will automatically convert on a 1 for 107.39 basis into shares of Common Stock upon the closing of the Issuer's initial public offering.